Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

122.83 +4.83 (+4.09%)
Streaming Delayed Price Updated: 10:52 AM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
News headline image
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
From BioNTech SE
Via GlobeNewswire
News headline image
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology ↗
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines. 
Via Benzinga
Topics Lawsuit
News headline image
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement ↗
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake ↗
Shares peaked near 62 in late 2021, but are now worth less than half of that. 
Via Investor's Business Daily
News headline image
Forecasting The Future: 15 Analyst Projections For BioNTech ↗
 
Via Benzinga
News headline image
Forecasting The Future: 8 Analyst Projections For BioNTech ↗
 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on BNTX Options ↗
 
Via Benzinga
News headline image
4 Reasons Pfizer Could Be a Value Play You Can't Miss
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71 
Via MarketBeat
News headline image
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Consumer Tech News (Sept 30-Oct 4): Latest Windows 11 Update Causing Trouble, Apple Accused Of Compelling Employees To Sign Illegal Agreements & More ↗
Major tech companies lobby against CA bill regulating AI, Apple faces legal complaints, iPhone users retain devices longer. Google warns Apple app removal. 
Via Benzinga
Topics Artificial Intelligence Law Enforcement
News headline image
Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research ↗
This AI aims to facilitate interdisciplinary collaboration and uncover unexpected connections in scientific research. 
Via Benzinga
Topics Artificial Intelligence
News headline image
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
From BioNTech SE
Via GlobeNewswire
News headline image
Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
News headline image
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
Via Investor's Business Daily
News headline image
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
From BioNTech SE
Via GlobeNewswire
News headline image
Here's Why Everyone's Talking About Summit Therapeutics ↗
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
Via The Motley Fool
News headline image
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions ↗
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and... 
Via Benzinga
News headline image
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio? ↗
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings. 
Via Benzinga
News headline image
Should You Buy Novavax Stock After This Regulatory Win? ↗
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
News headline image
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech ↗
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV... 
Via Benzinga
News headline image
Why Is Moderna Stock Trading Higher On Monday? ↗
Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu... 
Via Benzinga
News headline image
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows ↗
Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys. 
Via Benzinga
News headline image
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
From BioNTech SE
Via GlobeNewswire
News headline image
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
News headline image
UK, Taiwan Approve Moderna's Updated COVID-19 Shot ↗
The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.